News stories about Macrocure (NASDAQ:MCUR) have trended somewhat negative this week, according to AlphaOne. The research firm, a unit of Accern, scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Macrocure earned a daily sentiment score of -0.03 on AlphaOne’s scale. AlphaOne also assigned news coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the near term.

Shares of Macrocure (NASDAQ:MCUR) remained flat at $1.51 during trading on Monday. Macrocure has a 52 week low of $0.75 and a 52 week high of $3.20. The company has a 50 day moving average price of $1.51 and a 200 day moving average price of $1.54.

COPYRIGHT VIOLATION WARNING: “Macrocure (MCUR) Given Coverage Optimism Rating of -0.03” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at

About Macrocure

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

5 Day Chart for NASDAQ:MCUR

Receive News & Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related companies with's FREE daily email newsletter.